# Umbilical Cord Blood Megakaryocyte Injection (XJ-MK-002) for Cancer Therapy-Induced Thrombocytopenia (CTIT)

> **NCT07110090** · PHASE1 · RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 16 (estimated)

## Conditions studied

- Thrombocytopenia
- Cancer

## Interventions

- **BIOLOGICAL:** Umbilical Cord Blood Megakaryocyte Injection (XJ-MK-002)

## Key facts

- **NCT ID:** NCT07110090
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-28
- **Primary completion:** 2026-06
- **Final completion:** 2026-07
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2025-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07110090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07110090, "Umbilical Cord Blood Megakaryocyte Injection (XJ-MK-002) for Cancer Therapy-Induced Thrombocytopenia (CTIT)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07110090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*